CEPHALALGIA头痛
CEPHALALGIA(英文缩写 CEPHALALGIA),ISSN 0333-1024,eISSN 1468-2982,中文译名:头痛 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 6.075 | Q1 |
| 2022 | 4.900 | Q1 |
| 2023 | 5.000 | Q1 |
| 2024 | 4.600 | Q1 |
| 2025 | 5.800 | Q1 |
CEPHALALGIA 最新收录文献
-
1. Migraine attack prediction using wearable biosensor data.
PMID:日期:2026-09-01BackgroundMany migraine sufferers report difficulties in managing their attacks, leading to missed workdays, impaired cognitive function and reduced participation in social activities. This challenge underscores the importance of identifying reliable indicators of an impending attack. The present study aimed to develop and evaluate machine learning models for predicting migraine attacks based on continuous, non-invasive monitoring of autonomic nervous system activity.MethodsData from a wrist-worn biosensor device the Empatica EmbracePlus (Empatica Inc., Boston, MA, USA) capturing electrodermal activity, heart rate, skin temperature and metabolic equivalent of task were analysed using machine learning models to detect prodromal autonomic nervous system alterations and predict impending migraine headaches. Personalised models were developed using participant-specific model selection, whereas generalised transferability was assessed using a leave-one-participant-out approach.ResultsData from 27 participants were analysed, with an average monitoring period of 30.8 ± 12.9 days, during which 96 migraine attacks were recorded, corresponding to 3.6 ± 1.0 episodes per individual. Personalised prediction models, each reflecting a participant-specific best-selected configuration, achieved good overall predictive performance, with mean values of 0.82 ± 0.10 for accuracy, 0.75 ± 0.16 for precision, 0.72 ± 0.12 for recall and 0.73 ± 0.12 for the F1-score. The mean area under the receiver operating characteristic curve was 0.84 ± 0.10. Gaussian Naive Bayes was most frequently selected, accounting for 44% of valid participant-specific configurations. Generalised models provided above-chance performance in only one-third of participants.ConclusionsThis study supports the feasibility of migraine attack prediction using continuous physiological data from a wrist-worn biosensor analysed with personalised machine learning approaches.
-
2. Multimodal 7T MRI reveals subcortical structural, functional, iron accumulation, and glymphatic abnormalities in chronic migraine.
PMID:日期:2026-09-01BackgroundExploring the pathogenesis of chronic migraine (CM) remains a formidable challenge. While 7T MRI enables precise detection of microstructural alterations in subcortical nuclei and subregions in CM, comprehensive multimodal imaging studies are few. We therefore conducted a 7T multimodal imaging study to characterize subcortical nuclei and limbic subregions within the hypothalamus, thalamus, hippocampus, and amygdala alterations associated with migraine chronification and to determine the impact of medication-overuse headache (MOH) on CM brain changes.MethodsWe performed multimodal 7T MRI in 62 healthy controls (HCs), 62 episodic migraine (EM) patients, and 62 CM patients (31 with MOH). MRI measures included volumes, functional indicators (fractional amplitude of low-frequency fluctuation (fALFF) and regional homogeneity (ReHo)), quantitative susceptibility mapping (QSM), and diffusion tensor imaging analysis along the perivascular space, choroid plexus volume, and basal ganglia perivascular space (PVS) metrics for glymphatic function. Group differences and associations with clinical measures were assessed.ResultsAfter false discovery rate (FDR) correction, fALFF in the accumbens area (L) and mean individual PVS volume differed significantly among the three groups ( < 0.05). Both EM and CM showed lower left accumbens fALFF and greater PVS volume than HCs, whereas no significant difference was detected between EM and CM. No group effects survived FDR correction for regional volume, ReHo, QSM, or other PVS metrics. No significant differences were found between CM patients with and without MOH. Left accumbens fALFF was negatively correlated with the headache duration, whereas PVS volume was positively correlated with headache duration.ConclusionsMigraine was associated with reduced spontaneous activity in the left accumbens area and increased basal ganglia PVS volume. The absence of detectable differences between EM and CM suggests that these abnormalities may represent shared migraine-related features rather than changes that increase linearly with chronification. The findings implicate altered pain-reward processing and perivascular morphology, while indicating that the transition to CM may depend on changes that static regional measures do not capture.
-
6. Depressive and anxiety symptoms during CGRP-targeted migraine prevention: A systematic review and meta-analysis.
PMID:日期:2026-09-01BackgroundMigraine is frequently comorbid with depression and anxiety, conditions that amplify disease burden and may impair preventive treatment response. Calcitonin gene-related peptide (CGRP)-targeted therapies have demonstrated robust efficacy in reducing migraine frequency, with emerging evidence suggesting concurrent improvements in psychiatric symptom burden. However, findings derive from heterogeneous study designs and outcome instruments, limiting conclusions regarding consistency and magnitude of these effects.MethodsWe conducted a systematic review and meta-analysis of studies reporting changes in depressive and anxiety symptoms in adults with migraine receiving CGRP-targeted preventive therapies. PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and PsycINFO were searched from inception through July 2026. Eligible studies included randomised controlled trials, post hoc analyses, and real-world observational studies reporting validated self-report or clinician-rated symptom measures at baseline and follow-up. Risk of bias was assessed using the Jadad Scale for randomised trials and the Newcastle-Ottawa Scale for observational studies. Standardised mean differences with 95% confidence intervals were calculated using random-effects models.ResultsTwelve studies (n = 3603; 63% female) published between 2020 and 2026 met eligibility criteria, of which nine contributed to quantitative synthesis. Pooled analyses demonstrated consistent reductions in depressive symptoms across instruments at 3 months: Hospital Anxiety and Depression Scale - Depression subscale -1.35 points (95% CI, -1.63 to -1.07), Hamilton Depression Rating Scale -3.73 points (95% CI, -5.76 to -1.71), and Beck Depression Inventory -3.70 points (95% CI, -4.92 to -2.48). Anxiety outcomes improved similarly: Hospital Anxiety and Depression Scale - Anxiety subscale -1.50 points (95% CI, -2.45 to -0.55), Hamilton Anxiety Rating Scale -1.64 points (95% CI, -3.21 to -0.07), and Beck Anxiety Inventory -4.36 points (95% CI, -5.24 to -3.48). In the single placebo-controlled subgroup analysis, fremanezumab was numerically superior to placebo for depressive outcomes, though this difference did not reach statistical significance.ConclusionsCGRP-targeted therapies were consistently associated with reductions in depressive and anxiety symptom scores across multiple validated instruments, with improvements appearing to correlate with effective migraine control, although current study designs cannot differentiate between direct and indirect effects on psychiatric symptoms. Placebo-controlled evidence remains insufficient to draw firm conclusions, and adequately powered randomized controlled trials with psychiatric outcomes as prespecified endpoints are warranted before the nature and magnitude of these effects can be definitively characterized.
-
7. Establishing a core curriculum in headache medicine: Best practices from the international headache society education committee.
7. 建立头痛医学核心课程：国际头痛学会教育委员会的最佳做法PMID:日期:2026-09-01Headache disorders remain one of the most disabling and prevalent neurological diseases worldwide. Headache medicine and care have evolved tremendously over the past few years. In order to foster adequate education in headache medicine in medical school curricula and clinical residency programs, the Education Committee of the International Headache Society (IHS) updated the core curriculum in headache medicine for establishing core competencies in general neurologists and headache specialists. This document describes the background and methodical approach of the IHS in developing and updating the current core curriculum in headache medicine and presents the output of the endeavor. The process has been guided by international expert consultation, evidence-based content development, and alignment with evolving scientific and clinical advances. The 2026 updated Core Curriculum outlines a tiered approach for general neurologists and headache specialists, which includes advances in pathophysiology, diagnosis, therapeutics, multidisciplinary management, and internationally transferable training standards. This revised core curriculum will guide headache education worldwide and enable higher-quality patient care across a range of healthcare settings.
-
10. Development and external validation of a migraine analgesic usage (MAU) index for identifying high-severity migraine: A multi-center study.
PMID:日期:2026-09-01AimTo determine whether a two-variable scorecard combining monthly acute medication days and the six-item Migraine Treatment Optimization Questionnaire can identify high multidimensional migraine burden, defined operationally as a four-domain composite (monthly migraine days, acute medication days, pain intensity, and disability) score ≥50 (range 0-100), with sufficient discrimination and clinical utility for bedside triage.MethodsWe performed a cross-sectional analysis of baseline data from a multicenter, prospective, real-world migraine registry in China (enrolment January 2024 - December 2025). Adults with migraine and complete data for the four-domain composite and the six-item Migraine Treatment Optimization Questionnaire were included (total sample, 1161; derivation cohort, 344; external validation cohort, 817). A two-predictor logistic regression model was developed at the coordinating center and validated at the remaining centers. Bootstrap-adjusted discrimination and calibration were assessed. A categorical version of the model was converted into an integer scorecard (0-11 points) with decision-curve-derived triage zones.ResultsThe area under the receiver operating characteristic curve was 0.899 (95% confidence interval 0.863-0.935) in derivation and 0.866 (0.837-0.895) in external validation. Calibration in the validation cohort showed systematic overestimation (expected-to-observed ratio 1.85); after intercept recalibration, the Brier score decreased from 0.14 to 0.11. Decision curve analysis showed net benefit across threshold probabilities 0.10-0.50. In validation, the Green zone (score ≤2) included 313 participants (38.3%) with a negative predictive value of 0.98; the Yellow zone (score 3-4) included 180 (22.0%); and the Red zone (score ≥5) included 324 (39.7%) with a positive predictive value of 0.45. Monthly acute medication days accounted for most of the discriminative performance; the treatment-optimization component provided additional stratification, particularly in the intermediate medication-use range (4-14 days/month).ConclusionThe Migraine Analgesic Usage Index offers a concise, externally validated triage aid for identifying high multidimensional migraine burden as defined by the four-domain composite. It may help prioritize comprehensive assessment but does not replace clinical evaluation. Prospective studies should test whether index-guided triage improves decision quality and patient outcomes.Trial registrationChinese Clinical Trial Registry, https://www.chictr.org.cn/, ChiCTR2400083678.